Kornimate/medical-research-clean huggingface dataset:
molecular and morphologic characterization of circulating endothelial cells

Conditions: Acute Myocardial Infarction

Summary: the primary hypothesis of this study is that circulating endothelial cells (cecs) harbor key genetic and structural characteristics predisposing individuals to acute atherosclerotic plaque rupture and heart attack.

endothelial injury and inflammation are pivotal underlying processes that put patients at risk for catastrophic vascular events including acute myocardial infarction (heart attack) and stroke. we seek to accelerate scientific discovery through clinically meaningful, innovative translational research, and are collaborating in a trans-disciplinary effort to define the dna sequence of cecs and that of germ line dna, along with rna sequencing, mrna expression profiling, and ultrastructural characterization of cecs in order to better understand the mechanisms leading to acute arterial plaque rupture and embolization of arterial endothelial cells in patients with acute myocardial infarction. this will enable us to create a molecular fingerprint that could identify and preempt individuals from suffering from such debilitating vascular conditions.

Eligibility criteria:
inclusion criteria: 1. age 18 - 80 years old. 2. must be reliable, cooperative and willing to comply with all protocol-specified procedures if consented. 3. able to understand and grant informed consent 4. subjects must meet one of the following (a-c): 1. healthy control subjects not meeting any exclusion criteria for controls below 2. patients scheduled for an open vascular procedure of an arterial structure 3. patients with acute mi defined as: i. clinical history and symptoms consistent with acute mi and ii elevated cardiac markers (ckmb, troponin i or t) consistent with mi (abnormals are according to enrolling institution's lab standards) and iii. able to complete study enrollment (consent \& blood draw) within 48 hours of presentation to the study site. exclusion criteria: general exclusion criteria: 1. has a significant medical condition that in the investigator's opinion may interfere with the patient's optimal participation in the study. exclusion for healthy controls: 1. age greater than 35 2. previous history of coronary artery disease or mi 3. diabetes 4. peripheral arterial disease 5. hypertension (\>140/90 or on blood pressure medication) 6. sickle cell disease 7. acute or chronic kidney disease 8. acute or chronic vascular conditions, not otherwise specified 9. active or history of inflammation of connective tissue and vascular structures (i.e. vasculitis, rheumatoid arthritis)

Keywords: myocardial infarction (mi) circulating endothelial cells (cec) control group a: (vascular surgery) control group b: (healthy controls)
phase ii study of ap0302 5% versus a vehicle comparator

Conditions: Pain; Delayed Onset Muscle Soreness

Summary: this study is designed to evaluate the analgesic safety and efficacy of study drug (ap0302) applied topically every 6 hours as compared to a vehicle, in subjects experiencing delayed onset muscle soreness.

the purpose of this study is to evaluate the efficacy and safety of s-ibuprofen topical gel 5% in reducing pain/soreness associated with delayed onset muscle soreness (doms).

Eligibility criteria:
inclusion criteria: * no clinically significant medical conditions * bmi between 18-30 * negative drug, alcohol, pregnancy screens * other protocol-defined inclusion criteria may apply exclusion criteria: * no upper extremity workout in last 6 months * no job requiring heavy lifting * history of muscle disorders * allergy or intolerance to study drug * history of recent pain medication use * other protocol-defined exclusion criteria may apply

Keywords: muscle soreness
cluster randomised trial of improved sanitation in rural orissa, india

Conditions: Diarrhoea; Soil-transmitted Helminth Infection; Nutritional Status

Summary: the study is a cluster-randomized, controlled trial conducted among 100 villages (including approximately 3500 households and 20,000 people) in puri district, state of orissa, india. the study aims to assess the impact of the construction and use of latrines in rural settings on diarrhoeal disease, helminth infections and nutritional status. the study will also report on the cost and cost-effectiveness of the intervention and its impact on lost days at school and work as well as on expenditures on drugs and medical treatment. the study will document how the intervention actually impacts exposure to human excreta along principal transmission pathways by evaluating the impact on (i) faecal contamination of drinking water, (ii) the presence of mechanical vectors (flies) in food preparation areas, and (iii) the presence of faeces in and around participating households and villages. the study will also explore the extent to which different levels of acquisition and use of on-site sanitation among householders impact disease throughout the community.


Eligibility criteria:
inclusion criteria: village level: * little existing sanitation coverage (\<10%) * wateraid and implementing partners expects normal scale up * stable and reasonably acceptable water supply * no other wash interventions planned or anticipated in next 30 months * reasonable year-round access by road to permit household visits by surveillance staff household level: * presence of a child\<4 or a pregnant woman * consent to participate * reside permanently in the village
the impact of implementing nidcap on the developmental sensitivity of nurses caring for preterm infants

Conditions: Infant, Premature Development

Summary: the purpose of this study is to determine whether implementing the newborn individualized developmental care and assessment program increases nicu nurses' sensitivity in meeting the developmental care needs of preterm infants.

therapies that have brought about sharp decreases in neonatal mortality have not brought about similar decreases in neurodevelopmental morbidity for preterm infants. developmentally supportive care is nicu (neonatal intensive care unit) care that seeks to optimize the developmental course and outcomes for preterm infants. in controlled trials, implementation of the newborn individualized developmental care and assessment program (nidcap) has been associated with with positive medical and neurobehavioral outcomes. the purpose of this study is to examine the impact of implementing the nidcap on the developmental sensitivity of nurses caring for preterm infants in a tertiary level nicu in a children's hospital in the midwest. the nidcap program consists of 1) structured behavioral observations which are conducted at regular intervals during the preterm infant's hospitalization, 2) written plans which outline specific, individualized interventions to address the infant's unique developmental needs which are updated following each observation, and 3) consultations with the infant's caregivers to articulate the infant's current needs and plan. a convenience sample of 32 nicu nurses will be observed during a routine caregiving episode with one preterm infant before and another preterm infant after the implementation of the nidcap program with preterm infants in the nicu. following the observations, the nurse's developmental sensitivity will be scored using a standardized tool. the nurses' developmental sensitivity before the implementation of the nidcap program will be compared with their developmental sensitivity following nidcap implementation. informed consent will be obtained from the nurses participating in the study.

Eligibility criteria:
inclusion criteria: * be an rn, * be an employee of the nicu at the study site, * have completed the nicu nursing orientation at the study site, * work at least 0.4 fte in the nicu at the study site, and * be observed while caring for a preterm infant born at less than or equal to 36 weeks gestation and at less than or equal to 1500 grams exclusion criteria: * nurses will not be observed while caring for fullterm infants or preterm infants receiving heavy sedation or paralyzing medications.

Keywords: developmental care neonatal intensive care unit (nicu)
portal vein thrombosis in cirrhosis

Conditions: Hepatic Vein Thrombosis; Cirrhosis

Summary: this study evaluates the supervivence of cirrhotic patients that develop portal vein thrombosis in comparison to cirrhotic patients that do not develop portal vein thrombosis.

patients newly diagnosed with portal vein thrombosis by imaging tests, that evaluate the extent and exclude tumoral origin, will be included (informed consent previously signed). anticoagulant treatment will be initiated according to clinical guidelines (if there is no contraindication) first with lmwh (low molecular weight heparin) and later with dicoumarin. an abdominal ct will be performed to evaluate the extent and exclude tumoral origin; a gastroscopy to evaluate portal hypertension (and do prophylaxis if required) and thrombophilia study. patients will be followed by imaging and laboratory tests every 6 months; to evaluate the response to the treatment and detect any cirrhosis complication.

Eligibility criteria:
inclusion criteria: * cirrhosis diagnosed by liver biopsy or non-invasive methods/clinical, analytics or ultrasound usual criteria * portal vein thrombosis of newly diagnosed (defined as partial or complete obstruction of splenoportal vessels objectified by imaging with/without symptomatology) ≤ 6 months. * over 18 years old * want to participate (informed consent) exclusion criteria: * pregnant or lactating * patients with tumoral vein thrombosis or elevated alpha-fetoprotein or high suspicion of underlying neoplastic disease. * thrombocytopenia \< 25.000 . * patients with cavernomatosis or portal vein thrombosis already known. * patient refusal to participate * patients already treated with anticoagulants for other diseases (atrial fibrillation, pulmonary thrombosis...)

Keywords: portal vein thrombosis cirrhosis
longitudinal study of bone mineral density in survivors of solid pediatric cancers

Conditions: Osteoporosis

Summary: specific subgroups of children who survive treatment for childhood malignancies have been shown to develop relative osteopenia following chemotherapy and are felt to be at risk for developing osteoporosis later in life due to their inability to reach peak bone mass during childhood. based upon an earlier study in our department, the investigators reported conclusive evidence that approximately half of survivors of pediatric solid malignancies are at risk for these problems. however, the proportion of patients in our population that showed osteopenia/osteoporosis was lower than that in other similar cross-sectional studies in solid tumors such as osteosarcoma. the main difference between our report and the osteosarcoma study was duration of follow-up, with ours being shorter. longer follow-up may prove that a larger proportion of our patients are affected. the purpose is to perform a longitudinal follow-up study of bone mineral density using dual-energy x-ray absorptiometry (dxa) in adult survivors of solid pediatric tumors that were previously studied as subjects in our original cross-sectional study. the primary hypothesis is that the proportion of pediatric solid cancer survivors with significantly lower bone mineral density (bmd) compared to established age group controls will be increased with the additional time that has elapsed since the original study despite the fact that the patients are young and would not normally be expected to have osteopenia/osteoporosis at this age.

as above

Eligibility criteria:
inclusion criteria: * the 38 patients from the suny upstate medical center pediatric oncology long-term survivor clinic who were subjects in the original georg fund supported study will comprise the patient population if they are locatable and willing to participate. * patients must be less than 40 years of age to participate. exclusion criteria: * patients who have received interval treatment for acute lymphocytic leukemia (all) and those who have received subsequent cranial irradiation or total body irradiation (groups already known to be at high risk for osteoporosis) will be excluded. these would have had to have occurred in the interval since the original study, as these were also exclusion criteria for that study. in addition, any patient who received interval non-autologous bone marrow transplant will be excluded, as these patients may have graft versus host disease (also known to be associated with osteopenia).

Keywords: examine the risk of osteoporosis in survivors of solid pediatric cancers
study of intracellular nucleotide pools determination as biomarker of the efficacy of the induction treatment in acute myeloid leukemia

Conditions: Acute Myeloid Leukemia

Summary: treatment of acute myeloid leukemia (aml) consists in two main phases: induction and consolidation. standard chemotherapy combination for induction treatment associates cytarabine (arac), a nucleoside analog, and an anthracycline (most often daunorubucin). about 60-70% of patients achieved complete remission after this standard chemotherapy. as cytarabine competes with endogenous nucleotides to exert its activity, the aim of this protocol is to study in vivo the effect of intracellular nucleotide pools on the efficacy of the induction treatment. thus, intracellular nucleotides levels will be determined in peripheral blood mononuclear cells of patients with acute myeloid leukemia before treatment, and results will be compared with the efficacy of the treatment. this parameter will be assessed by the achievement of complete remission.


Eligibility criteria:
patients inclusion criteria: * age over 18 years * acute myeloid leukemia * standard induction chemotherapy with cytarabine and daunorubicin * patients who received the information and did not object to participate to the study patients exclusion criteria: - patients with acute myeloid leukemia 3 healthy volunteers inclusion criteria : * adults without known hematological disease, * adults who received the information and did not object to participate in the study healthy volunteers exclusion criteria : - volunteers with known hematological disease.
effect of 12 weeks of resistive exercises versus aerobic exercises in overweight hypertensive postmenopausal women

Conditions: Exercise

Summary: sixty postmenopausal women participated in this study from gynecological outpatient clinic, at al-zahra universal hospital, al azhar university, and cairo. they were first diagnosed to be hypertensive in their early postmenopausal period .their blood pressure ranged between 140/90mmhg to 170/105mmhg, their ages ranged from 50 to 60 years and their body mass index ranged from 30:35 kg/m2.

the participants were divided randomly according to closed envelop into three equal groups in number: group a (re) consisted of twenty women who participated in the resistive exercise program. group b (ae) group: consisted of twenty women who participated in an aerobic exercise program. all patients in both groups (a \& b) participated in the exercises three times per week for twelve weeks and every session lasted for 45 min and continues their antihypertensive medication

Eligibility criteria:
inclusion criteria: * all women diagnosed as essential hypertension. * all women must be in their early postmenopausal period exclusion criteria: * lesion to higher centers leading to hypertension (embolism) * any cardiovascular disease * premature menopause * surgical menopause * severe hypertension * diabetic * under treatment of hormonal therapy.

Keywords: resistive exercises aerobic menopause hypertension
registry of patients with mpns in taiwan

Conditions: Myeloproliferative Neoplasms

Summary: myeloproliferative neoplasms (mpns) are a group of clonal hematologic malignancies with great variation in reported patient life expectancy and are characterized by a relatively indolent course which can be complicated by thromboembolic events and transformation to acute myeloid leukemia (aml). the mpns in the 2016 world health organization (who) classification of myeloid neoplasms consist of polycythemia vera (pv), essential thrombocythemia (et), primary myelofibrosis (pmf) including prefibrotic/early stage and over fibrotic stage, chronic myeloid leukemia, other (rare) disorders such as chronic neutrophilic leukemia and chronic eosinophilic leukemia and mpn unclassifiable (mpn-u). the prevalence and genetic characteristics of patients with mpns in taiwan are still unknown. molecular tests which are required for the diagnosis of mpns are not available in many hospitals which hamper the accurate diagnosis and subtype classification of mpns. moreover, the information of current therapeutic strategy for mpns in most medical centers in taiwan is also not available. the purpose of this mpn registry is to collect clinical data, molecular characteristics, treatment details and response to therapy, occurrence of complications during the course, disease progression to secondary myelofibrosis from pv or et and secondary aml (saml) transformation as well as survival. the clinical and molecular data including the high molecular risk (hmr) genes will be examined and correlated with treatment outcomes in taiwanese mpn patients. the molecular diagnostic laboratory at chang gung memorial hospital-linkou is a college of american pathologists (cap)-accredited lab which provides high quality of molecular genetic tests for hematologic malignancies. the three driver gene mutations are the major criteria for the diagnosis of mpn, the methodologies of mutational analyses have been well set up for the clinical use in this lab. in addition, this lab is also equipped with facilities for the detection of mutated genes which were recently identified as hrm category (presence of any of asxl1, ezh2, srsf2, idh1 or idh2), and mutations of other epigenetic regulators or splicing factors.


Eligibility criteria:
inclusion criteria: 1. male and female patients aged ≥ 20 years. 2. patient who had a confirmed diagnosis according to the 2016 revised who criteria with a ph (-) mpn. exclusion criteria: 1. patients do not fulfill the diagnostic criteria of mpn by who 2016 classification. 2. patients unwilling to sign informed consent.
dispensing evaluation of a galyfilcon a prototype lens and a marketed contact lens

Conditions: Myopia

Summary: the purpose of this study is to compare visual acuity and redness of eyes between a prototype contact lens and an already marketed contact lens.


Eligibility criteria:
inclusion criteria: * the subject is a current spherical soft contact lens wearer and willing to wear the study lenses on a daily wear basis for the duration of the study. * the subject's optimal vertexed spherical equivalent distance correction must be between -1.00 and - 5.00d. * any cylinder power must be ≤ -0.75d. * the subject must have visual acuity best correctable to 20/25+3 or better for each eye. * the subject must read and sign the statement of informed consent. * the subject must appear able and willing to adhere to the instructions set forth in the clinical protocol. exclusion criteria: * ocular or systemic allergies or disease which might interfere with contact lens wear. * systemic disease or use of medication which might interfere with contact lens wear. * clinically significant (grade 3 or 4) corneal edema, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear. * clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection which might interfere with contact lens wear. * any ocular infection. * any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear. * pregnancy or lactation. * diabetes. * infectious diseases (e.g. hepatitis, tuberculosis) or an immuno-suppressive disease (e.g. hiv). * habitual contact lens type is toric, multifocal, or is worn as extended wear.
effect of stellate ganglion block on new atrial fibrillation after coronary artery bypass grafting

Conditions: Stellate Ganglion Block

Summary: post-operative new-onset atrial fibrillation (poaf) is one of the most common arrhythmias in adults after direct intracardiac surgery with extracorporeal circulation. the incidence of poaf in coronary artery bypass grafting (cabg) is approximately 30%. poaf can lead to an increased risk of complications such as stroke, heart failure, and acute kidney injury, which not only prolongs the patient's hospital stay, but also increases hospital costs and mortality. operation, extracorporeal circulation, and the patient's underlying conditions (such as age, gender, hypertension, and diabetes), which cause sympathetic activation, inflammatory response, and myocardial ischemia in the organism. the stellate ganglion block (sgb) regulates the sympathetic tone of the innervated nerves and thus the autonomic function of the body. sgb can effectively regulate the sympathetic-parasympathetic imbalance. also, sgb may exert some anti-inflammatory effects. in this study, ultrasound-guided sgb was used in cabg patients to investigate its effect on the occurrence of poaf.


Eligibility criteria:
inclusion criteria: * patients undergoing first-time and elective coronary artery bypass grafting; * asa grade ii-iv； * the preoperative ecg showed sinus heart rate. exclusion criteria: * the patient refused to participate in this study; * surgical procedures include any other type of heart surgery in addition to cabg； * allergic to known general anesthesia drugs; * patients with a history of neck surgery or abnormal neck anatomy; * patients with contraindications to sgb.
study investigating the interactions of bone and hematopoiesis in the elderly

Conditions: Myelodysplastic Syndromes

Summary: the prospective boheme study is designed to evaluate the correlation between bone marrow function and skeletal health in elderly patients (\>= 60 years) with or without pre-existing myelodysplastic syndromes (mds).


Eligibility criteria:
inclusion criteria group 1 (mds group): * age ≥60 years * with known or suspected mds (according who, \<20% blast count) * written informed consent inclusion criteria group 2 (control group): * age ≥60 years * undergoing elective knee or hip replacement therapy * normal blood count (defined by hb ♀ \>12 g/dl, ♂ \>13 g/dl; anc \>1.8x10\^9/l; plt \>100x10\^9/l) * written informed consent exclusion criteria group 1 (mds group) + 2 (control group): * history of bilateral total hip replacement prior to study * control group only: diagnosis of mds or aml prior to study * dementia defined as mmse score of \<24 * renal insufficiency with an egfr \<30 ml/min * liver cirrhosis child-pugh b or c * active infection (hiv, hepatitis b or c, tuberculosis) * heart insufficiency nyha iii or iv or severe cardiac valve disease * prior allogeneic stem cell transplantation

Keywords: mds myelodysplastic syndromes